These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 23915741

  • 1. Endocrine therapy for advanced/metastatic breast cancer.
    Schiavon G, Smith IE.
    Hematol Oncol Clin North Am; 2013 Aug; 27(4):715-36, viii. PubMed ID: 23915741
    [Abstract] [Full Text] [Related]

  • 2. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
    Robertson JF, Howell A, Gorbunova VA, Watanabe T, Pienkowski T, Lichinitser MR.
    Breast Cancer Res Treat; 2005 Jul; 92(2):169-74. PubMed ID: 15986127
    [Abstract] [Full Text] [Related]

  • 3. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
    Cheung KL, Owers R, Robertson JF.
    Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
    [Abstract] [Full Text] [Related]

  • 4. Endocrine therapy for early breast cancer.
    Hussain SA, Williams S, Stevens A, Rea DW.
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
    [Abstract] [Full Text] [Related]

  • 5. New approaches to reverse resistance to hormonal therapy in human breast cancer.
    Weinberg OK, Marquez-Garban DC, Pietras RJ.
    Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
    [Abstract] [Full Text] [Related]

  • 6. Breast cancer adjuvant endocrine therapy.
    Cigler T, Goss PE.
    Cancer J; 2007 Aug; 13(3):148-55. PubMed ID: 17620763
    [Abstract] [Full Text] [Related]

  • 7. Primary endocrine therapy as an approach for patients with localized breast cancer deemed not to be surgical candidates.
    Hilton J, Arnaout A, Clemons M.
    Curr Opin Support Palliat Care; 2014 Mar; 8(1):53-8. PubMed ID: 24299966
    [Abstract] [Full Text] [Related]

  • 8. [Adjuvant treatment of breast cancer. Endocrine therapy].
    Mouridsen HT, Andersen J.
    Ugeskr Laeger; 2007 Sep 10; 169(37):3072-6. PubMed ID: 17877951
    [Abstract] [Full Text] [Related]

  • 9. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.
    Cardoso F, Bischoff J, Brain E, Zotano ÁG, Lück HJ, Tjan-Heijnen VC, Tanner M, Aapro M.
    Cancer Treat Rev; 2013 Aug 10; 39(5):457-65. PubMed ID: 22840697
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hormonal therapy for postmenopausal breast cancer: the science of sequencing.
    Miller WR, Bartlett JM, Canney P, Verrill M.
    Breast Cancer Res Treat; 2007 Jun 10; 103(2):149-60. PubMed ID: 17039263
    [Abstract] [Full Text] [Related]

  • 13. Adjuvant endocrine therapies for postmenopausal women with early breast cancer: standards and not.
    Dellapasqua S, Castiglione-Gertsch M.
    Breast; 2005 Dec 10; 14(6):555-63. PubMed ID: 16188442
    [Abstract] [Full Text] [Related]

  • 14. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ.
    Oncology; 2005 Dec 10; 69(1):1-9. PubMed ID: 16088229
    [Abstract] [Full Text] [Related]

  • 15. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
    Harichand-Herdt S, Zelnak A, O'Regan R.
    Expert Rev Anticancer Ther; 2009 Feb 10; 9(2):187-98. PubMed ID: 19192957
    [Abstract] [Full Text] [Related]

  • 16. Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.
    Iwase H, Yamamoto Y.
    Int J Clin Oncol; 2015 Apr 10; 20(2):253-61. PubMed ID: 25673474
    [Abstract] [Full Text] [Related]

  • 17. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ.
    Cancer; 2006 Jun 15; 106(12):2576-82. PubMed ID: 16703595
    [Abstract] [Full Text] [Related]

  • 18. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
    Fentiman IS.
    Int J Clin Pract; 2006 Jun 15; 60(6):689-93. PubMed ID: 16805754
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
    Ohno S.
    Clin Breast Cancer; 2016 Aug 15; 16(4):238-46. PubMed ID: 27151773
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.